Home Contact us News Site map
  About us     Reference projects     Matrix & Pharma  
• Matrix & Pharmaceuticals
• Our technology
• The whole is more
     then the sum of its parts
• Our thrombin inhibitor.
• More drug discovery
     projects
 
The advantages and capabilities of the CADDIS process have been validated in a number of additional projects:
   • National Cancer Institute Simulations
   • Antibiotics
   • Fungicide
In simulations on the database of the US National Cancer Institute of the National Institute of Health {http://www.nci.nih.gov} a study was maid to test Matrix' ability to rapidly optimize and identify compounds. The database consists of the experimental results of the impact of more than 30,000 compounds on 6 different types of cancer.

Starting with an initial selection of only 50 compounds and additional 20 compounds per cycle the activity of the best molecule was improved by a magnitude of over 4. More than 50% of the 12 most active compounds were found. We repeated the simulation over several runs using a different initial selection of compounds. The results were repeated in all simulation runs.

Results are summarised in table 1 and figure 1.
[table]

Table 1 Improvement of the activities of the compounds (simulations on the NCI database, see text). The criterion was the mean GI-50 activity over all 6 criteria listed in the database. Also given the NCI internal number. In figure 1 the appendant 3D structures are shown.


Figure 1: Evolution of the structures in simulations on the NCI database, see text. Shown are the structures of the best molecules of each cycle. Cycles 0--3 are shown in the top line and cycles 4,6--8 in the bottom line (from left to right). Note the ability to 'jump' between diverse motives and chemical structures.

Some additional comments on the results:
1. In total there are 31097 entries in the database.
2. 14781 entries do not show any effect on the targets < 4.1, all values below 4.0
     were set to 4.0 for simplicity.
3. The mean activity of the molecules is 4.50.
4. Only 25 molecules (<0.1%) show activities higher than 9.00.

The distribution of the mean GI-50 over 6 cancer types for all entries in the NCI database is shown in figure 2.



Figure 2: Statistical distribution of the mean GI-50 over 6 cancer types for all 31097 entries in the NCI database in logarithmic scaling.


watch the modelling demo

This film shows the progress of one optimization cycle targeting the activity on melanoms. Initially the activity (measured as the GI-50 value, being on a logarithmic scale) of the best compound found so far is 4.80. The best molecule is shown in its 3D structure. Subsequently the optimization process is illustrated. The horizontal axis represents true activity and the vertical represents the corresponding predicted activity values. In the beginning the models are not specific to internal relations within the data. You can see this from the fact that almost all molecules are predicted to have essentially the same activity, the points scatter around a horizontal line representing the mean value. This is reflected by a root of the mean squared (RMS) error of almost 0.5 (0.497).

Using all information from the 20 molecules available in the simulation at this moment in time the Matrix modeling technology was applied to this data set: molecule structures on the one hand and activities on the other hand. What you now watch is the part of the process which completely runs within the computer; no additional data is fed into the process at this time. Continuously the points approach the diagonal, which represents the outcome for perfect models for the given data points. In parallel the RMS error is reduced to under 0.07. Finally 10 molecules are proposed based on the final models which than are checked for activities in the database. The best of which is shown and has an activity of over 9.5. Representing a 50,000 fold activity. The associated 3D structure indeed shows almost no similarity to the best compound from the initial cycle.


The development of effective antibiotics faces a major problem: The identification of a mechanism that is very specific for the bacteria. A non-specific mechanism would inevitably demonstrate numerous and severe side-effects, i.e. a very high toxicity of the drug. The identification of such a mechanism is tricky and risky. The solution was thus provided by the CADDIS process: If when applying the molecules to both the bacteria and human cells as a whole cell and measuring their reaction on the drug and when the behavior of the human cell remains unchanged while the growth of the bacteria is significantly suppressed (and further requirements you impose on the drug candidates are fulfilled too), then a true candidate is identified.

In the actual project the compounds were tested with respect t their impact on a human cell line, the impact on the growth rate of the bacteria and further important criteria such as metabolic stability. Without restricting the CADDIS process to any specific mechanism it was possible to automatically model and identify a variety of specific mechanisms within only a few optimization cycles. Matrix was able to develop within six cycles and approximately 100 compounds per cycle a very effective drug candidate without any negative impact on the human cell line. The process also resulted in the identification and exclusion of many common compounds known for their antibiotic activity due to their severe side-effects.


Figure 3: Comparison of one of the Matrix antibiotics with a common reference drug (Geneticin).



Two major challenges have to be met in green biotech: Efficacy (large areas have to be covered, thus the amount of drug per area must be small) and environmental compatibility. The compound must not be toxic against a broad variety of plants and animals.
A test suite was set up including major fungi of interest, human cell lines, chemical properties and even parts of leafs. This program ensured the required compatibility and selectivity of the compound. However this approach is only feasible for reasonable costs if not too many compounds have to be tested. The CADDIS process offers exactly such an opportunity.
After few CADDIS process cycles and comparably a very small amount of tested compounds interesting candidates were identified with unprecedented properties.


Figure 4: Impact of two Matrix compounds on the growth of two of the tested fungi. Matrix-1 is a very early compound, Matrix-2 stems from later phases. As can be seen Matrix-2 is able to significantly reduce the growth rates of two of the most harmful fungi for crops.



© 2004 Matrix Advanced Solutions   |  Terms of usecreated by egozi